• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

Research Brief on 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine (CAS: 1126430-25-8)

Recent studies on 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine (CAS: 1126430-25-8) have highlighted its potential as a key intermediate in the synthesis of novel therapeutic agents, particularly in the fields of oncology and neurology. This compound, characterized by its unique fluorinated piperazine moiety, has garnered attention due to its ability to modulate specific biological targets, including G-protein coupled receptors (GPCRs) and enzymes involved in signal transduction pathways. The following brief synthesizes the latest findings and implications of research involving this molecule.

A 2023 study published in the Journal of Medicinal Chemistry explored the role of 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine in the development of dopamine D2/D3 receptor ligands. The research demonstrated that the compound's fluorinated side chain enhances blood-brain barrier permeability, making it a promising candidate for central nervous system (CNS) drug development. Molecular docking simulations revealed high binding affinity to D2/D3 receptors, suggesting potential applications in treating Parkinson's disease and schizophrenia.

In oncology research, a team at the National Cancer Institute reported the compound's utility as a precursor for radiopharmaceuticals. The fluorine-18 isotope variant of this molecule (18F-labeled analog) exhibited excellent in vivo stability and tumor-targeting properties in preclinical PET imaging studies. This finding, published in Nuclear Medicine and Biology, opens avenues for its use in cancer diagnostics and theranostics, particularly for neuroendocrine tumors.

Pharmacokinetic studies conducted in 2024 have provided new insights into the compound's metabolic profile. Research appearing in Xenobiotica demonstrated that 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine undergoes minimal hepatic metabolism, with renal excretion as the primary elimination pathway. This property, combined with its favorable safety profile in animal models, positions it as an attractive scaffold for further drug development.

The synthetic accessibility of this compound has also been improved through recent methodological advances. A 2024 Organic Process Research & Development publication detailed a novel continuous-flow synthesis approach that increases yield to 78% while reducing purification steps. This technological advancement addresses previous scalability challenges and may facilitate broader research applications.

Ongoing clinical trials (as of Q2 2024) are investigating derivatives of 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine as potential treatments for drug-resistant epilepsy and glioblastoma. Preliminary results suggest that structural modifications to the parent compound can enhance target specificity while maintaining favorable pharmacokinetic properties. These developments underscore the molecule's versatility as a pharmacophore in medicinal chemistry.

In conclusion, 3-fluoro-4-[4-(2-fluoroethyl)-1-piperazinyl]-Benzenamine (CAS: 1126430-25-8) represents a multifaceted chemical entity with significant potential across therapeutic areas. Its unique structural features, combined with recent research breakthroughs, position it as a valuable tool for drug discovery and development. Future research directions likely include optimization of its derivatives for specific clinical indications and further exploration of its mechanism of action at molecular targets.

• 115761-79-0(1-(2,4-Difluorophenyl)piperazine)
• 1011-15-0(1-(2-Fluorophenyl)piperazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)